19 Jun 2017 07:00
Integumen plc
("Integumen" or "the Company")
Integumen wins new orders for Labskin, its research grade living skin equivalent
Integumen (LSE: SKIN), the personal health care company developing and commercialising technology and products for the human integumentary system, is pleased to announce it has received orders from La Prairie, Merck & Co., Inc. ("Merck"), and Galderma S.A ("Galderma").
La Prairie
Integumen has received orders from La Prairie, the Swiss-based beauty company with an unparalleled commitment to excellence, luxury and the science of skincare. The brand is owned by Beiersdorf AG, a German personal care company based in Hamburg, manufacturing personal care products and pressure-sensitive adhesives.
The orders are for Integumen to conduct Efficacy Trials using Labskin as the platform, which will test certain materials in La Prairie's range of products.
Labskin is a three-dimensional human skin equivalent (HSE) model that resembles the discrete biological layers found in human skin. Since the EU ban on testing of cosmetics on animals, the Company is ideally positioned to take advantage of the fact that HSEs are being increasingly used by developers operating in the dermatology space such as La Prairie.
Merck
Merck, the international developer, manufacturer and distributor of pharmaceuticals has signed an evaluation order with Integumen for the Company's Labskin HSE model.
Galderma
Galderma is a pharmaceutical subsidiary specializing in the research, development and marketing of dermatological treatments, and is a wholly-owned subsidiary of Nestlé. Galderma has ordered Labskin for testing of materials and formulations in their HQ in Lausanne, Switzerland.
Declan Service, CEO of Integumen, said:
"We are delighted to receive these orders from such reputable blue chip clients. With an ever-increasing focus on the human microbiome, Labskin's advantage of being able to host bacteria in a similar environment to that of human skin is proving to be an attractive option for companies focussed on R&D in skincare. While relatively small in revenue terms, these orders not only demonstrate our ability to commercialise our products and technologies which is what we promised to do at IPO, but also our ability to build relationships with established companies. In addition, we have secured our first order for Labskin under the three-year OEM (Original Equipment Manufacturer) supply agreement we signed with our partner in Germany, all of which is testament to the hard work our sales and marketing team continues to do - deliver new revenue streams."
Integumen plc | Declan Service, CEO
| + 353 (0) 87 770 5506 |
SPARK Advisory Partners Limited (Nominated Adviser)
| Neil Baldwin/Sean Wyndham-Quin | +44 (0) 113 370 8974 |
Turner Pope Investments (TPI) Ltd
| Ben Turner/James Pope
| +44 (0) 20 3621 4120 |
Cardew Group | Shan Shan Willenbrock David Roach
| +44 (0) 20 7930 0777 integumen@cardewgroup.com
|
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. This contrasts with an RNS Regulatory announcement which is required to be notified under the AIM Rules for Companies.